New Indication for Bardet-Biedl syndrome (BBS) Effective October 1, 2023 On September 5, Rhythm issued a press release announcing the new ICD-10-CM code specific to Bardet-Biedl syndrome (BBS) ‒ Q87.83 ‒ effective October 1, 2023. Read Rhythm Press Release This new ICD-10-CM code specific to BBS has the potential to improve patient identification and ongoing monitoring, which may help providers and payers: Accurately…
FDA Consumer Update Safely Treating Molluscum Using YCANTH™ Recommendation Issued by the FDA The FDA has issued two consumer updates since June 2023, focusing on the management of Molluscum Contagiosum. The first FDA alert was issued in June 2023, and an updated alert was published following the approval of YCANTH in August. Below is the full text of the consumer update published by the FDA on August 23, 2023: View Full FDA Article FDA Article Highlights "Safely Treating Molluscum, a Common Skin Condition" If you’re bothered by bumps on your skin, don’t try to diagnose yourself or treat your condition with products that haven’t been approved by the U.S. Food and Drug Administration. Instead, visit a health care professional for a proper diagnosis and to make a treatment plan. One common condition that some people try to self-diagnose and treat is molluscum contagiosum, a skin infection caused by a virus. But by doing so, you run the risk of delaying the diagnosis and treatment of a…
NOW APROVED: APHEXDA TM (motixafortide) for injection APHEXDA™ is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. APHEXDA TM (motixafortide) for injection, for subcutaneous use U.S. Approval: 2023 NDC Dosing Form and Strength WAC Pricing 82737-0073-01 For Injection: 62 mg as a lyophilized powder in a single-dose vial for reconstitution $5900 per vial IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS APHEXDA is contraindicated in patients with a history of serious hypersensitivity reactions to motixafortide. WARNINGS AND PRECAUTIONS Anaphylactic Shock and Hypersensitivity Reactions : Anaphylactic shock and hypersensitivity reactions have occurred. Premedicate all patients with a triple drug premedication regimen that includes an H1 -antihistamine, an H2 blocker, and a leukotriene inhibitor approximately 30-60 minutes prior to each dose…
Effective August 18, 2023 Effective August 18th, 2023 EYLEA ® HD (aflibercept) Injection 8 MG has been approved as a new single source drug by the FDA Suggested Billing and Coding for EYLEA HD** HCPCS CODES EYLEA HD NDC* PACKAGE DESCRIPTION WAC Per Package J3490: Unclassified drugs J3950: Unclassified Biologicals 61755- 0 050-01 xxxxxxxxxxxxxxxxxxxxx Vial kit containing one EYLEA HD 8 mg (0.07 mL of a 114.3 mg/mL solution) single-dose glass vial, one 18-gauge x 1½-inch, 5-micron, filter needle for withdrawal of the vial contents, one 30-guage x ½-inch injection needle for intravitreal injection and one 1-mL syringe for administration, one Prescribing Information $2625.00 *Note that the product’s NDC has been “zero-filled” to ensure creation of an 11-digit code that meets general billing standards. The zero-fill location is indicated in bold. **This information is provided for informational purposes only, is subject to change, and should not be construed as legal or medical advice.…
Email content sponsored by Apellis Pharmaceuticals, Inc. Email content sponsored by Apellis Pharmaceuticals, Inc. Effective for claims on and after October 1, 2023: J2781 SYFOVRE (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) SELECT SAFETY INFORMATION SYFOVRE is contraindicated in patients with ocular or periocular infections, and in patients with active intraocular inflammation. Please see additional Important Safety Information below. PRODUCT SPECIFICATIONS 1 : Permanent J-Code J2781 , effective October 1, 2023 CMS Long Descriptor 2 Injection, pegcetacoplan, intravitreal, 1 mg* * Dose descriptor is assigned by CMS; please see full prescribing information for approved dosing NDC Number 10-digit: 73606-020-01 and 11-digit: 73606-0020-01 CPT Code 3 67028: Intravitreal injection of a pharmacologic agent, separate procedure Geographic Atrophy ICD-10-CM Diagnosis Codes 4 Non-exudative age-related…
Funded and Developed by GSK: NOW APPROVED: Coding and Pricing: CPT Code Presentation Carton NDC Number WAC Pricing 90679 Outer Carton of ten doses 58160-0848-11 $280/dose* Please take a moment to update any of your reimbursement, billing, and ordering systems to reflect this change. *Wholesale acquisition cost (or WAC), also known as list price, is the price to wholesalers and warehousing chains, not including prompt pay, stocking or distribution allowances, or other discounts, rebates, or chargebacks. WAC may not represent prices charged to other customers, including specialty distributors, and is not the price that most patients pay for the product. For more information on the prices patients pay, please check with the patient's healthcare provider. WAC price as of 07/23. Indication AREXVY is indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in individuals 60 years of age and older. Important Safety…
Learn more about a new treatment option This email is being sent by BuyandBill.com on behalf of Verrica Pharmaceuticals Inc. Please see Important Safety Information below and full Prescribing Information . Announcing the FDA approval of YCANTH ™ (cantharidin) Topical Solution 0.7% For the treatment of molluscum contagiosum for patients 2 years of age and older. Potential Billing Codes for YCANTH* Code Type Code Descriptor ICD-10-CM B08.1 Molluscum contagiosum CPT 17110 Destruction (e.g., laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions up to 14 lesions CPT 17111 Destruction (e.g., laser surgery, electrosurgery, cryosurgery, CPT 17111 chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions 15 or more lesions HCPCS J Code J3490 Unclassified Drugs HCPCS C Code C9399 Unclassified drug or Biologic; for use in…
WARNING: PERSONNEL AND EQUIPMENT FOR MONITORING AND RESUSCITATION, AND RISKS FROM CONCOMITANT USE WITH OPIOID ANALGESICS AND OTHER SEDATIVE-HYPNOTICS See full Prescribing Information for complete Boxed Warning. Effective July 1, 2023: J2249: injection remimazolam, 1 mg for Byfavo® Byfavo (remimazolam) for injection, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less. HCPCS Code Code Descriptor NDC Number How Supplied WAC Per Package WAC Per HCPCS Unit J2249 Injection, remimazolam, 1 mg 71390-011-00 One vial Intravenous Solution Reconstituted 20 mg $2.067 $2.067 J2249 Injection, remimazolam, 1 mg 71390-011-11 Ten vials Intravenous Solution Reconstituted 20 mg $413.40 $2.067 Please update billing and claims systems to include J2249 for dates of service after July 1, 2023. For additional information regarding Byfavo, please contact your Key Account Manager or visit Byfavo.com Indication Byfavo is…
Now Approved: A ONCE-WEEKLY echinocandin Available Summer 2023 REZZAYO TM (rezafungin for injection) is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical safety and efficacy data. How Supplied: NDC Package Description WAC Pricing 70842-240-01 200 mg as a solid (cake or powder) in a single-dose vial for reconstitution $1950/vial Potential Diagnosis Codes: ICD-10-CM Description B37.1 Pulmonary candidiasis B37.7 Candidal sepsis B37.81 Candidiasis of other sites B37.82 Candidal enteritis B37.89 Other sites of candidiasis INDICATION AND USAGE REZZAYO TM (rezafungin for injection) is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical…
SAMSUNG BIOEPIS Biosimilar Market Report 2 nd Edition, Q3 2023 Download Here In this second edition of our report, we have included the 8 Humira biosimilars' WAC price that have launched within pharmacy benefits and updated the most recent market share and ASP trends of all molecules for biosimilar(s) that have launched in the US. Moving forward each Market Report will consist of comprehensive updates on pricing and market penetration for all marketed biosimilars in the US. We invite you to download the 2 nd Samsung Bioepis Biosimilar Market Report here: Download Here © 2023 Samsung Bioepis Co., Ltd. All Rights Reserved. 6/2023. BuyandBill.com SAMSUNG…
No alerts match your filters.
The Comparative Report puts ASP, the Medicare payment limit, WAC and AWP for up to 15 drugs on one timeline. Ten-plus years of monthly history, per HCPCS unit.
Included with BuyandBill Pro for $37/month billed annually.
Trastuzumab class, seven products
Actual published ASP, Jan 2015 to Aug 2026.